LIXTE BIOTECHNOLOGY HOLDINGS, INC. Stockholders Equity

Quick Answer

LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Stockholders Equity of $9.66 million for fiscal year 2025.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $9.66M +1068.3%
2024 $827.2K -79.3%
2023 $3.99M -22.7%
2022 $5.17M +7.8%
2021 $4.79M -4.4%
2020 $5.01M +105.9%
2019 $2.43M -41.0%
2018 $4.13M +314.6%
2017 $995.0K +363.3%
2016 $214.8K -31.2%
2015 $312.3K +17.5%
2014 $265.9K +12.5%
2013 $236.3K -84.2%
2012 $1.49M +1787.9%
2011 $79.0K -95.4%
2010 $1.74M +33.4%
2009 $1.30M +502.1%
2008 -$323.5K -185.8%
2007 $376.9K -31.8%
2006 $552.6K +3878.5%
2005 -$14.6K
2005 $0.00

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $4.91M +259.4% +654.0%
June 30, 2025 $651.5K -71.0% -43.8%
March 31, 2025 $1.16M -62.9% +40.1%
December 31, 2024 $827.2K -79.3% -39.5%
September 30, 2024 $1.37M -72.2% -39.1%
June 30, 2024 $2.25M -16.6% -28.2%
March 31, 2024 $3.13M -23.4% -21.7%
December 31, 2023 $3.99M -22.7% -18.9%
  • LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed an increase of +1068.3% in Stockholders Equity compared to the prior fiscal year.
  • The most recent figure is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment